MET and non-small cell lung carcinoma: In addition, the drug is being investigated in association with INC280, a specific MET inhibitor (based on the potential escape pathway for third-generation EGFR TKIs) in an ongoing phase Ib/II trial in patients with advanced EGFR mutant NSCLC (NCT02335944), and with nivolumab, an anti-PD-1 monoclonal antibody in a phase II trial in EGFR mutant/T790M+ NSCLC patients who have progressed on first-line EGFR TKI (NCT02323126).